Correlation Engine 2.0
Clear Search sequence regions

The aim of the present study was to examine the influence of the topical carbonic anhydrase-II-inhibitor dorzolamide hydrochloride (Trusopt) in regarding to behaviour of intraocular eyepressure after Nd:YAG-laser-capsulotomy. The study was carried out as a double-blind-test. In a period of nine months, 120 patients underwent Nd:YAG-laser-capsulotomy. One group was given dorzolamide hydrochloride (Trusopt), the other group (placebo) remained without medication. The intraocular pressure was measured before capsulotomy and four hours post-op. For statistical evaluation the t-test of not-associated spot-checks was performed. The prophylactic use of the topical carbonic anhydrase-II-inhibitor dorzolamide hydrochloride (Trusopt) after nd:YAG-laser-capsulotomy shows a highly significant lowering of intraocular pressure, i.e. 1.09 mm Hg in the average. It was demonstrated that a single dose of dorzolamide hydrochloride (Trusopt) after Nd:YAG-laser-capsulotomy could lower intraocular pressure significantly. Prophylactical usage of dorzolamide hydrochloride (Trusopt) is a useful method to prevent the increase of intraocular pressure and thus to protect the eye against hazardous damage.


C Lachmann, K M Jörg, R Trinkmann. Postoperative behavior of intraocular pressure after posterior Nd:YAG laser capsulotomy--critical evaluation in preventive administration of local carbonic anhydrase II inhibitor dorzolamide hydrochloride (Trusopt)]. Klinische Monatsblätter für Augenheilkunde. 1998 Dec;213(6):326-30

Expand section icon Mesh Tags

Expand section icon Substances

PMID: 10048009

View Full Text